Comparability of antibody response to a booster dose of 7-valent pneumococcal conjugate vaccine in infants primed with either 2 or 3 doses.
In this cohort study we compared IgG antibody levels between infants immunized with 7-valent CRM197-conjugated pneumococcal vaccine (PCV-7) at 2, 4 and 11 months and at 2, 3, 4 and 11 months of age, as measured by double adsorption ELISA. Pre- and post-booster levels following the 2+1- and 3+1-dose schedule were comparable for 5 out of 7 serotypes except for serotypes 6B and 19F. The proportion of children reaching post-booster antibody thresholds were comparable except for 6B (>or=1.0 microg/ml and >or=5.0 microg/ml) and 19F (>or=5.0 microg/ml). Surveillance studies are warranted for vaccine impact on 6B and 19F disease cases after reduced-dose PCV-7 schedules.
Rodenburg
Gerwin D
GD
Department of Pediatric Immunology and Infectious Diseases, University Medical Center Utrecht, The Netherlands. g.d.rodenburg@umcutrecht.nl
van Gils
Elske J M
EJ
Veenhoven
Reinier H
RH
Jones
Nienke
N
Tcherniaeva
Irina
I
Hak
Eelko
E
van Alphen
Loek
L
Berbers
Guy A M
GA
Sanders
Elisabeth A M
EA
D000907:Antibodies, Bacterial / Q000097:blood* / Q000276:immunology; D004306:Dose-Response Relationship, Immunologic; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006801:Humans; D007117:Immunization, Secondary; D007223:Infant; D008297:Male; D009426:Netherlands; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000276:immunology; D013997:Time Factors
D000907:Antibodies, Bacterial; D022242:Pneumococcal Vaccines